BioAge Labs, Inc. (NASDAQ:BIOA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

BioAge Labs, Inc. (NASDAQ:BIOA) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $43.50.

A number of analysts have commented on BIOA shares. BTIG Research started coverage on BioAge Labs in a research report on Wednesday, May 13th. They set a “buy” rating and a $40.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Needham & Company LLC initiated coverage on BioAge Labs in a research report on Friday, March 27th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, Oppenheimer initiated coverage on BioAge Labs in a research report on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price objective on the stock.

Institutional Trading of BioAge Labs

Several institutional investors and hedge funds have recently made changes to their positions in BIOA. Russell Investments Group Ltd. purchased a new stake in shares of BioAge Labs in the third quarter valued at $27,000. CWM LLC lifted its position in BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after buying an additional 1,053 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after buying an additional 5,976 shares during the period. Walleye Capital LLC purchased a new position in BioAge Labs during the second quarter worth about $64,000. Finally, Bank of America Corp DE lifted its position in BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the period.

BioAge Labs Stock Performance

BIOA opened at $21.47 on Tuesday. The business’s fifty day moving average is $17.54 and its two-hundred day moving average is $17.57. The company has a market cap of $954.41 million, a price-to-earnings ratio of -8.95 and a beta of 0.94. BioAge Labs has a one year low of $4.07 and a one year high of $24.00.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Friday, May 8th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.19. The company had revenue of $2.77 million for the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. On average, analysts predict that BioAge Labs will post -2.68 EPS for the current fiscal year.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.